TMCnet News

Nodality Launches PathPro™ Chronic Lymphocytic Leukemia (CLL) Panels Based on Leading Single Cell Network Profiling (SCNPTM) Platform to Enhance Pharmaceutical R&D
[April 02, 2015]

Nodality Launches PathPro™ Chronic Lymphocytic Leukemia (CLL) Panels Based on Leading Single Cell Network Profiling (SCNPTM) Platform to Enhance Pharmaceutical R&D


Nodality, Inc., which is focused on solving drug development challenges, announced today the availability of its new PathPro™ Chronic Lymphocytic Leukemia (CLL) panels. These panels are designed to characterize cell pathways associated with disease signaling at the single cell level and to analyze the activity of therapeutics commonly used or in development to treat CLL. Earlier this year, Nodality introduced its first PathPro products, which leverage the unique capabilities of Nodality's proprietary multiparametric flow cytometry platform to study the functional activity of customer therapeutics and identify disease subgroups and differential activities in pathways or diseases. In addition to the PathPro CLL panels, Nodality has launched the PathPro JAK-STAT, PathPro TLR, and the PathPro AML panels. The Company anticipates additional PathPro product launches in 2015.

Laura Brege, CEO and President of Nodality, Inc., stated, "We are pleased with the reception of our PathPro products and are excited to expand our offerings to drug developers. PathPro CLL panels allow researchers the opportunity to study potency and specificity of newly developed biologics, small molecule inhibitors, and chemotherapeutics developed for use in the treatment of CLL."

Nodality's PathPro products are based on the Company's broad knowledge and experience in diverse signaling pathways and in interrogating signaling at the single cell level in numerous cell types. For each PathPro product, customers are able to select modulators, pathways, cell types and donor sample types to be interrogated in targeted, small-scale studies. The results provide critical insights into the functional impact of drugs and drug candidates in disease sub-groups, identify differential in vitro activities, pathway-specific profiles and/or disease profiles, while addressing mechanism of action (MOA), efficacy (IC50s) and comparison of compound activities.

  • PathPro™ CLL panels

    Nodality's PathPro Chronic Lymphocytic Leukemia (CLL) panels enable analysis of multiple functional signalig pathways across cell subsets, including CLL and normal B cells, T cells, and monocytes. By applying this technology, an association between B-cell receptor signaling and disease progression has been demonstrated (Cesano, et al., Haematologica (2013) 98, 626), and CLL B cells have also been shown to respond to CD40 and Toll-Like Receptor modulation. As with other PathPro and SCNP offerings, the PathPro CLL panels allow for high-throughput, quantitative flow cytometry analysis of current and investigational therapeutics as single agents or in combination. For more information on the PathPro CLL panels, please visit: http://nodality.com/products-disease-offerings-cll.html.



In addition to the four PathPro products already launched, Nodality will be introducing additional PathPro panels this year: PathPro TCR, PathPro BCR, PathPro PD-1, PathPro IMR, and PathPro Th1/2/17 Polarization. The new panels are designed to target additional drug development needs in autoimmune diseases, hematological cancers and immuno-oncology.

About Single Cell Network Profiling


Nodality's proprietary Single Cell Network Profiling (SCNP) technology, a multiparametric flow cytometry-based platform, provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology by characterizing cell signaling networks in millions of cells at the single cell level. It creates competitive advantages in addressing many of the most pressing challenges in drug discovery and development. SCNP technology, coupled with Nodality's proprietary data analysis and visualization tools, uniquely reveals complex functional biology to inform more effective drug development decisions.

Originally developed at Stanford University, SCNP does not require physical isolation of cell subsets and therefore provides real time information on cell-cell interactions, identifies the functional signaling capacity of rare cell subsets (such as drug-resistant cells and stem cell populations) reveals the functional consequences of epigenetic mutations and enables the interrogation of immune cell communication and dysfunction in disease.

About Nodality

Nodality is a life science company whose technology platform, SCNP, bridges the gap left by traditional R&D approaches. Nodality provides clinically actionable solutions throughout the full discovery and development process, including disease profiling, drug profiling, clinical development, and life cycle management. Nodality's team has expertise in identifying solutions across a broad therapeutic landscape, with a focus on immunology and oncology, including immuno-oncology. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the discovery and development of new therapeutic compounds. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp.

For more information on Nodality, please visit www.nodality.com.


[ Back To TMCnet.com's Homepage ]